Talphera (TLPH) Profit After Tax (2010 - 2026)
Talphera (TLPH) posted Profit After Tax of -$4.3 million for Q2 2026, down 68.7% on a QoQ basis from -$2.6 million in Q1 2026, and down 23.59% year-over-year from -$5.6 million in Q2 2025.
Analysis
Talphera (TLPH) Profit After Tax (2010 - 2026) Analysis & Trends
Talphera has reported Profit After Tax for 17 years, with the latest figure at -$4.3 million in Q2 2026.
- On a quarterly basis, Profit After Tax fell 23.59% year-over-year to -$4.3 million in Q2 2026; TTM through Jun 2026 was -$15.1 million, a 33.36% decrease from a year earlier, with the FY2025 full-year figure at -$14.4 million, down 10.45% from the prior year.
- Profit After Tax was -$4.3 million for Q2 2026 at Talphera, down from -$2.6 million in the prior quarter.
- The five-year high for Profit After Tax was $70.7 million in Q2 2022, with the low at -$8.7 million in Q1 2022.
- Average Profit After Tax over 5 years is -$184277.8, with a median of -$3.9 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax jumped 817.32% in 2022, then slumped 136.46% in 2024.
- Over 5 years, Profit After Tax stood at -$5.9 million in 2022, then advanced by 23.9% to -$4.5 million in 2023, then jumped by 58.6% to -$1.9 million in 2024, then plunged by 101.71% to -$3.8 million in 2025, then fell by 14.32% to -$4.3 million in 2026.
- The last three Profit After Tax figures came in at -$4.3 million (Q2 2026), -$2.6 million (Q1 2026), and -$3.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.02 Bn | 176.84 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 131.54 Bn | 123.69 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.23 Bn | 55.04 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.88 Bn | 30.59 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Talphera | 93.28 Mn | 93.28 Mn | - | -4.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.31 Mn |
| Mar 31, 2026 | -2.56 Mn |
| Dec 31, 2025 | -3.77 Mn |
| Sep 30, 2025 | -4.44 Mn |
| Jun 30, 2025 | -3.49 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | -1.87 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -3.95 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.37 Mn |
| Mar 31, 2023 | -8.15 Mn |
| Dec 31, 2022 | -5.94 Mn |
| Sep 30, 2022 | -6.75 Mn |
| Jun 30, 2022 | 70.66 Mn |
| Mar 31, 2022 | -8.67 Mn |
| Dec 31, 2021 | -7.92 Mn |
| Sep 30, 2021 | -8.38 Mn |